Serum peptidomic profiling and peptide mass fingerprinting reveal signatures associated with peroxisomal and mitochondrial pathways in MMVD-associated cardiorenal syndrome in dogs
Abstract
Cardiorenal syndrome in dogs, particularly those with myxomatous mitral valve degeneration (MMVD), involves complex neurohormonal interactions, yet molecular mechanisms linking heart and kidney dysfunction remain poorly understood. This study aimed to identify serum peptide and protein signatures that differentiate disease stages and clarify pathophysiology. We hypothesized that alterations in the serum peptide mass fingerprint and protein profile would serve as sensitive biomarkers for kidney disease progression in MMVD-affected dogs. Dogs were classified into five groups following ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dog and IRIS Staging of chronic kidney disease (CKD): Healthy, MMVD Stage B1, MMVD Stage C without azotemia, MMVD Stage C with azotemia, and CKD IRIS Stage 2. Serum peptide profiling was performed using Matrix-Assisted Laser Desorption/Ionization - Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for peptide mass fingerprint analysis and Nanoscale Liquid Chromatography-Tandem Mass Spectrometry for protein identification. MALDI-TOF MS effectively discriminated healthy dogs from diseased groups through discrete clustering in Partial Least-Squares Discriminant Analysis plots. Proteomic profiling identified 100 statistically significant proteins, with a critical subset of shared proteins including Peroxisomal biogenesis factor 14, Glutaredoxin-2, Creatine kinase mitochondrial 2, and Selenocysteine…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.